Current Clinical Trials

Department: Oncology
Diagnosis: Gynecology
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: CTSU -NCI
Indentifier #: NCT01366183
Title: GOG-0273, Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: ECOG
Indentifier #: NCT00828009
Title: E6508, A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer after Definitive Chemoradiation
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sponsor: ECOG
Indentifier #: NCT01107626
Title: E5508, Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Department: Oncology
Diagnosis: Hematology- Lymphoma
Principal Investigator: Lash MD, Bradley
Sponsor: CALGB
Indentifier #: NCT01286272
Title: CALGB 50904, A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND # 58443) and Bendamustine in Patients With Untreated Follicular Lymphoma
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Lash MD, Bradley
Sub-Investigator(s):
Sponsor: CALGB
Indentifier #: NCT00499330
Title: CALGB 140503 - A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 cm) Peripheral Non-Small Cell Lung Cancer
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Agheli MD, Aref
Sub-Investigator(s):
Sponsor: Amgen
Indentifier #: none
Title: Amgen 20130110; Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Amgen
Indentifier #:
Title: Amgen 20130110; Prospective Study of the Relationship between Chemotherapy Dose Intensity and Mortality in Early-Stage (I-III) Breast Cancer Patients Neulasta
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: AbbVie
Indentifier #: NCT02032277
Title: M14-011, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of the Addition of a PARP Inhibitor Plus Carboplatin Versus the Addition of Carboplatin in Combination with Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sponsor: Astra Zeneca
Indentifier #: NCT02000622
Title: D0819C00003, A Phase III, Open Label, Randomized, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients with germline BRCA1/2 Mutations
Department: Oncology
Diagnosis: Gastrointestinal - Pancreas
Principal Investigator: Lash MD, Bradley
Sponsor: Pfizer
Indentifier #: NCT01525550
Title: A6181202, A Single Arm Open-Label International Multi Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent®) In Patients With Progressive Advanced Metastatic Well Differentiated Unresectable Pancreatic Neuroendocrine Tumors